Breaking News, Financial News

Financial Report: Biogen Idec

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Biogen Idec 4Q Revenues: $893 million (+26%) 4Q Earnings: $201 million (+84%) FY Revenues: $3.2 billion (+18%) FY Earnings: $638 million (+193%) Comments: FY07 growth was primarily driven by Tysabri, Rituxan and Avonex sales. Through the Tysabri partnership with Elan, Biogen Idec  recognized revenue of $90 million in the quarter and $229.8 million for the year. 4Q06 and FY2006 Tysabri revenues were $17.6 million and  $35.8 million, respectively. The safety data for Tysabri continu...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters